<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>文章列表 on 神经纤维瘤资讯小屋</title>
    <link>http://localhost:1313/posts/</link>
    <description>Recent content in 文章列表 on 神经纤维瘤资讯小屋</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>zh-cn</language>
    <lastBuildDate>Fri, 03 Apr 2026 10:00:00 +0800</lastBuildDate><atom:link href="http://localhost:1313/posts/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>深度科普｜被千万病友忽视的NF1头号致残隐患：神经纤维瘤病合并脊柱侧弯</title>
      <link>http://localhost:1313/posts/nf1-scoliosis-guide/</link>
      <pubDate>Fri, 03 Apr 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/nf1-scoliosis-guide/</guid>
      <description>脊柱侧弯是NF1最常见且最容易被忽视的严重并发症之一。本文系统解析NF1脊柱侧弯的发病机制、危险信号、筛查方案及最新治疗策略。</description>
    </item>
    
    <item>
      <title>神经纤维瘤病诊疗指南（2025年版）</title>
      <link>http://localhost:1313/posts/nf1-clinical-guidelines-2025/</link>
      <pubDate>Thu, 02 Apr 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/nf1-clinical-guidelines-2025/</guid>
      <description>整理2025版神经纤维瘤病诊疗指南核心内容，包括病因、临床表现、辅助检查及诊断标准</description>
    </item>
    
    <item>
      <title>FDA批准米达美替尼（Gomekli）用于成人及儿童NF1丛状神经纤维瘤治疗</title>
      <link>http://localhost:1313/posts/mirdametinib-fda-approval/</link>
      <pubDate>Wed, 01 Apr 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/mirdametinib-fda-approval/</guid>
      <description>FDA正式批准米达美替尼（Gomekli）用于治疗2岁及以上NF1相关症状性丛状神经纤维瘤患者，成为首款覆盖成人与儿童全人群的MEK抑制剂</description>
    </item>
    
    <item>
      <title>司美替尼：丛状神经纤维瘤患儿的治疗新希望</title>
      <link>http://localhost:1313/posts/selumetinib-nf1-treatment/</link>
      <pubDate>Tue, 31 Mar 2026 14:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/selumetinib-nf1-treatment/</guid>
      <description>解析司美替尼在儿童丛状神经纤维瘤中的治疗作用、疗效特点及用药注意事项，帮助家长科学认识这一靶向药物</description>
    </item>
    
    <item>
      <title>罕见病帮扶指南：神经纤维瘤家庭可享受的福利</title>
      <link>http://localhost:1313/posts/nf1-support-policy/</link>
      <pubDate>Tue, 31 Mar 2026 12:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/nf1-support-policy/</guid>
      <description>整理神经纤维瘤家庭可申请的医保报销、医疗救助、教育支持及公益帮扶政策，帮助患者降低经济压力</description>
    </item>
    
    <item>
      <title>区分NF1与NF2：读懂两类常见神经纤维瘤病</title>
      <link>http://localhost:1313/posts/nf1-vs-nf2/</link>
      <pubDate>Tue, 31 Mar 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/nf1-vs-nf2/</guid>
      <description>全面解析NF1与NF2的区别，包括症状、发病部位与干预重点，帮助患者正确识别与管理疾病</description>
    </item>
    
    <item>
      <title>神经纤维瘤病1型（NF1）核心科普知识</title>
      <link>http://localhost:1313/posts/nf1-basic-guide/</link>
      <pubDate>Mon, 30 Mar 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/nf1-basic-guide/</guid>
      <description>全面介绍NF1的发病机制、典型症状、治疗方式与日常护理，为患者及家庭提供核心科普信息</description>
    </item>
    
    <item>
      <title>司美替尼获批成人NF1丛状神经纤维瘤适应症 填补成人治疗空白</title>
      <link>http://localhost:1313/posts/selumetinib-pnf-adult-nf1/</link>
      <pubDate>Sun, 29 Mar 2026 10:00:00 +0800</pubDate>
      
      <guid>http://localhost:1313/posts/selumetinib-pnf-adult-nf1/</guid>
      <description>司美替尼正式获批成人NF1丛状神经纤维瘤适应症，成人患者首次拥有靶向治疗选择，关键临床数据与意义解读</description>
    </item>
    
    <item>
      <title>我的第一篇文章</title>
      <link>http://localhost:1313/posts/my-first-post/</link>
      <pubDate>Tue, 24 Mar 2026 00:00:00 +0000</pubDate>
      
      <guid>http://localhost:1313/posts/my-first-post/</guid>
      <description>首页显示的简介文字</description>
    </item>
    
  </channel>
</rss>
